COHBAR, INC. (OTCMKTS:CWBR) Files An 8-K Other EventsItem 8.01
On July 12, 2018, CohBar, Inc. issued a press release announcing its initiation of a Phase 1a/1b safety and biomarker study of CB4211, its lead candidate under development as a potential treatment for non-alcoholic steatohepatitis (NASH) and obesity. A copy of the press release is attached hereto as Exhibit 99.1.
|Item 8.01||Financial Statements and Exhibits|
The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:
|99.1||CohBar, Inc. press release dated July 12, 2018.|
CohBar, Inc. ExhibitEX-99.1 2 f8k071218ex99-1_cohbarinc.htm COHBAR,…To view the full exhibit click